I think we are safe. The roundtable appears to be discussing "Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer" (https://ascopubs.org/doi/full/10.1200/JCO.20.03420), which focuses on clinical progress. FTO is not mentioned anywhere in the report, likely as it is preclinical for everyone except Race.
I would think the wealth of work presented in the report would leave no time for discussion on an even greater body of preclinical pathways under investigation. I could be completely wrong however as this is way out of my wheelhouse.
I think we are safe. The roundtable appears to be discussing...
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
0.020(1.55%) |
Mkt cap ! $217.2M | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.31 | $1.26 | $71.25K | 55.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 200 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 5950 | 3 |
View Market Depth
| Last trade - 16.10pm 26/04/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.31 |
Change
0.020 ( 2.18 %) |
||||
| Open | High | Low | Volume | ||
| $1.30 | $1.31 | $1.26 | 10789 | ||
| Last updated 15.59pm 26/04/2024 ? | |||||
| RAC (ASX) Chart |